Pharma Promotion / Legal commentary
Legal commentary (10 jurisdictions)
32 records since 1990, judged by Jev for relevance, jurisdiction, type and importance.
2026 6
- United StatesLegal commentary2026-07-30ICLGEvolving Regulatory Landscape for Healthcare Communications
- European UnionLegal commentary2026-07-30ICLGEvolving Regulatory Landscape for Healthcare Communications
- KoreaLegal commentary2026-07-30iclg.comEvolving Regulatory Landscape for Healthcare Communications
- European UnionLegal commentary2026-07-28www.hlc.comPharmaceutical advertising under the EU pharma law package
- United StatesLegal commentary2026-04-01eYLS (Yale Law School)Prescribing Drug Advertising Regulations in the Age of Social Media
- United StatesLegal commentary2026-02-12Milbank QuarterlyRegulating Direct‐to‐Consumer Prescription Drug Advertising in the United States
2021 1
- United StatesLegal commentary2021-03-01PubMedThe Law and Practice of Off-Label Prescribing and Physician Promotion.
2019 1
- United StatesLegal commentary2019-01-01Open Scholarship Institutional Repository (Washington University in St. Louis)Addressing the Threshold: Regulating Off-Label Drug Promotion
2017 1
- United StatesLegal commentary2017-01-01Seton Hall University eRepository (Seton Hall University)“Pharmaceutical Promotion in Interactive Media – How the Statute and Regulations Applied in Digital Era”
2015 3
- United StatesLegal commentary2015-11-18Journal of Law and the BiosciencesOff-label drug promotion and the ephemeral line between marketing and education
- United StatesLegal commentary2015-01-01bepress Legal RepositoryWhat Is "False or Misleading" Off-Label Promotion?
- United StatesLegal commentary2015-01-01bepress Legal RepositoryOff-Label Promotion, the First Amendment, and Practically Addressing Antibiotic Resistance
2014 3
- United StatesLegal commentary2014-12-31University of North Carolina School of Law Scholarship Repository (University of North Carolina Hospitals)Prospects for Regulation of Off-label Promotion in an Era of Expanding Commercial Speech Protection
- United StatesLegal commentary2014-01-01Penn Carey Law Legal Scholarship Repository (University of Pennsylvania)Off-Label Drug Promotion and the First Amendment
- United StatesLegal commentary2014-01-01eYLS (Yale Law School)FDA Involvement in Off-label Use: Debate Between Richard Epstein and Ryan Abbott
2012 2
- United StatesLegal commentary2012-02-01Biotechnology Law ReportPharmaceutical Advertising Often Not in Compliance with FDA Regulations
- United StatesLegal commentary2012-01-01Digital USD (University of San Diego)The Informational and Institutional Theories of Off-Label Promotion
2011 2
- United StatesLegal commentary2011-07-01Defense Counsel JournalWhat Every Pharmaceutical and Medical Device Company Should Know: False Claims Act Cases Based on Off-Label Promotion Promise to Increase with the Healthcare Act and the Bad Ad Program
- CanadaLegal commentary2011-01-01eYLS (Yale Law School)Direct-to-consumer advertising of pharmaceuticals on television: a charter challenge
2009 1
- United StatesLegal commentary2009-01-01bepress Legal RepositoryREGULATING DIRECT-TO-CONSUMER ADVERTISING WITH TORT LAW: IS THE LAW FINALLY CATCHING UP WITH THE MARKET?
2007 1
- United StatesLegal commentary2007-01-01bepress Legal RepositoryThe Difficult Case of Direct-to-Consumer Drug Advertising
2006 1
- United StatesLegal commentary2006-01-01Digital Access to Scholarship at Harvard (DASH) (Harvard University)Federal Preemption in the Area of Direct-to-Consumer (DTC) Advertising of Prescription Drugs
2005 2
- United StatesLegal commentary2005-10-01Defense Counsel JournalThe Learned Intermediary Doctrine and Beyond: Exploring Direct-to-Consumer Drug Advertising Liability in the New Millennium
- United StatesLegal commentary2005-01-01bepress Legal RepositoryFalse Claims Act Liability for Off-Label Promotion of Pharmaceutical Products
2004 1
- United StatesLegal commentary2004-11-01Hospital PharmacyDirect-to-Consumer Advertising of Prescription Drugs: Emerging Legal and Regulatory Issues
2002 1
- ChinaLegal commentary2002-01-01Digital Access to Scholarship at Harvard (DASH) (Harvard University)U.S. Drug Manufacturers Beware: Application of the PRC Antibribery Law to Drug Marketing and Promotional Practices in China
2000 3
- United StatesLegal commentary2000-08-03Digital Commons-DePaul (DePaul University)Direct Advertising of Prescription Drugs: The Duty to Warn and the Learned Intermediary Rule
- United StatesLegal commentary2000-01-01Digital Access to Scholarship at Harvard (DASH) (Harvard University)Promotion of Unapproved Uses of Approved Drugs and Devices: An Analysis under the First Amendment
- United StatesLegal commentary2000-01-01bepress Legal RepositoryDirect-to-Consumer Advertising of Prescription Drugs: After a Decade of Speculation, Courts Consider Another Exception to the Learned Intermediary Rule
1997 2
- United StatesLegal commentary1997-08-01Virginia Law ReviewClosing the Channels of Communication: A First Amendment Analysis of the FDA's Policy on Manufacturer Promotion of "Off-Label" Use
- United StatesLegal commentary1997-01-01EngagedScholarship @ Cleveland State University (Cleveland State University)Blinded by the Hype: Shifting the Burden When Manufacturers Engage in Direct to Consumer Advertising of Prescription Drugs
1993 1
- United StatesLegal commentary1993-01-01Scholarship @ Cornell Law (Cornell University)Bypassing the Learned Intermediary: Potential Liability for Failure to Warn in Direct-to-Consumer Prescription Drug Advertising